Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review
Open Access
- 9 February 2023
- Vol. 15 (4), 1102
- https://doi.org/10.3390/cancers15041102
Abstract
Inflammatory Bowel Disease (IBD) is a category of autoimmune diseases that targets the destruction of the gastrointestinal system and includes both Crohn’s Disease and Ulcerative Colitis (UC). Patients with IBD are at a higher risk of developing colorectal cancer (CRC) throughout their lives due to chronically increased inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) are potential chemopreventative agents that can inhibit the development of CRC in persons without IBD. However, the use of NSAIDs for CRC chemoprevention in IBD patients is further complicated by NSAIDs’ induction of damage to the bowel mucosal layer and ulcer formation. There has been a push in new research on chemopreventative properties of certain NSAIDs for IBD. The purpose of this umbrella review is to investigate the potential of low-dose NSAID compounds as chemopreventative agents for patients with IBD. This paper will also suggest future areas of research in the prevention of CRC for patients with IBD.This publication has 69 references indexed in Scilit:
- Colorectal cancer in inflammatory bowel disease: What is the real magnitude of the risk?World Journal of Gastroenterology, 2012
- Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort studyAlimentary Pharmacology & Therapeutics, 2011
- Effect of aspirin and NSAIDs on risk and survival from colorectal cancerGut, 2010
- Gastroduodenal Mucosal Injury in Patients Taking Low-Dose Aspirin and the Role of Gastric Mucoprotective Drugs: Possible Effect of RebamipideJournal of Clinical Biochemistry and Nutrition, 2010
- Novel agents for cancer prevention based on nitric oxideBiochemical Society Transactions, 2007
- Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel DiseaseGastroenterology Clinics of North America, 2006
- Chemoprevention for colon cancer: New opportunities, fact or fiction?Scandinavian Journal of Gastroenterology, 2006
- Rofecoxib (Vioxx) voluntarily withdrawn from marketCMAJ : Canadian Medical Association Journal, 2004
- Nonsteroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomasEmergencias, 2004
- Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004